Eli Lilly on a record $20B buying spree — momentum play on the pharma giant
Eli Lilly has announced over $20 billion in acquisitions so far in 2026, a record spending spree aimed at expanding beyond its blockbuster weight-loss drugs. Meanwhile, Goldman Sachs just raised its S&P 500 target to 8,000 on booming earnings expectations.
Idea
Eli Lilly is spending record amounts — over $20 billion this year alone — to buy up companies and build its next wave of drugs beyond the obesity franchise. That kind of aggressive deal-making signals management sees huge value and wants to lock it in before competitors do. Historically, when a dominant pharma company goes on a buying spree, its own stock tends to rise as investors price in future revenue from new drugs. The broader market is also getting a boost: Goldman just raised its S&P 500 year-end target to 8,000 on strong earnings, creating a favorable backdrop for mega-cap stocks like Lilly.